Diagnosing Lymphangioleiomyomatosis from Glycoprotein Non-Metastatic Melanoma Protein B

Overview

About this study

The purpose of this study is to analyze if levels of glycoprotein non-metastatic melanoma protein B be elevated in patients with LAM..

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Women ≥ 18 yrs.
Diagnosed with LAM using one or more of the following methods:
- Lung Biopsy;
- Elevated VEGF-D;
- Chylous Ascites;
- Chylous Pleural Effusions;
- Renal Angiomyolipomas.
Chest imaging (X-ray or CT scan).

Exclusion Criteria:

Current treatment with Sirolimus for LAM.
Diagnosis of Tuberculosis.
History of organ transplantation.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/17/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Misbah Baqir, M.B.B.S.	Closed for enrollment	Contact information: Kale Daniel (507) 266-4541 Daniel.Kale@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Misbah Baqir, M.B.B.S.

Closed for enrollment

Contact information:

Kale Daniel

(507) 266-4541

Daniel.Kale@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials